Immatics N.V.
(IMTX - NASDAQ)
9,56 USD
📋 Profilo Aziendale

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States.

|